Impact of a paediatric-adult care transition programme on the health status of patients with sickle cell disease: study protocol for a randomised controlled trial (the DREPADO trial).
Identifieur interne : 000182 ( Main/Exploration ); précédent : 000181; suivant : 000183Impact of a paediatric-adult care transition programme on the health status of patients with sickle cell disease: study protocol for a randomised controlled trial (the DREPADO trial).
Auteurs : Delphine Hoegy [France] ; Nathalie Bleyzac [France] ; Alexandra Gauthier-Vasserot [France] ; Giovanna Cannas [France] ; Angélique Denis [France] ; Arnaud Hot [France] ; Yves Bertrand [France] ; Pauline Occelli [France] ; Sandrine Touzet [France] ; Claude Dussart [France] ; Audrey Janoly-Dumenil [France]Source :
- Trials [ 1745-6215 ] ; 2020.
Descripteurs français
- KwdFr :
- Adaptation psychologique (MeSH), Adolescent (MeSH), Auto-efficacité (MeSH), Autosoins (MeSH), Conscience immédiate (MeSH), Drépanocytose SC (physiopathologie), Drépanocytose SC (psychologie), Drépanocytose SC (sang), Essais contrôlés randomisés comme sujet (MeSH), Femelle (MeSH), Gestion de la douleur (MeSH), Humains (MeSH), Hémoglobine S (MeSH), Mâle (MeSH), Qualité de vie (MeSH), Réadmission du patient (MeSH), Transition aux soins pour adultes (MeSH), Émotions (MeSH), État de santé (MeSH), Études multicentriques comme sujet (MeSH).
- MESH :
- physiopathologie : Drépanocytose SC.
- psychologie : Drépanocytose SC.
- sang : Drépanocytose SC.
- Adaptation psychologique, Adolescent, Auto-efficacité, Autosoins, Conscience immédiate, Essais contrôlés randomisés comme sujet, Femelle, Gestion de la douleur, Humains, Hémoglobine S, Mâle, Qualité de vie, Réadmission du patient, Transition aux soins pour adultes, Émotions, État de santé, Études multicentriques comme sujet.
English descriptors
- KwdEn :
- Adaptation, Psychological (MeSH), Adolescent (MeSH), Awareness (MeSH), Emotions (MeSH), Female (MeSH), Health Status (MeSH), Hemoglobin SC Disease (blood), Hemoglobin SC Disease (physiopathology), Hemoglobin SC Disease (psychology), Hemoglobin, Sickle (MeSH), Humans (MeSH), Male (MeSH), Multicenter Studies as Topic (MeSH), Pain Management (MeSH), Patient Readmission (MeSH), Quality of Life (MeSH), Randomized Controlled Trials as Topic (MeSH), Self Care (MeSH), Self Efficacy (MeSH), Transition to Adult Care (MeSH).
- MESH :
- chemical : Hemoglobin, Sickle.
- blood : Hemoglobin SC Disease.
- physiopathology : Hemoglobin SC Disease.
- psychology : Hemoglobin SC Disease.
- Adaptation, Psychological, Adolescent, Awareness, Emotions, Female, Health Status, Humans, Male, Multicenter Studies as Topic, Pain Management, Patient Readmission, Quality of Life, Randomized Controlled Trials as Topic, Self Care, Self Efficacy, Transition to Adult Care.
Abstract
BACKGROUND
Thanks to advancements in medical care, a majority of patients with sickle cell disease (SCD) worldwide live beyond 18 years of age, and therefore, patients initially followed in paediatric departments are then transferred to adult departments. This paediatric-adult care transition is a period with an increased risk of discontinuity of care and subsequent morbidity and mortality. During this period, the patient will have to manage new interlocutors and places of care, and personal issues related to the period of adolescence. To take into consideration all these aspects, an interesting approach is to use the whole system approach to the patient, as presented in the biopsychosocial approach. The aim of this trial is to evaluate the impact of the proposed biopsychosocial paediatric-adult transition programme.
METHODS
The DREPADO study is a multicentre randomised control trial comparing a control group (Arm A) to an interventional group with a paediatric-adult transition programme based on a biopsychosocial approach (Arm B). To be included, patients should have the SS, SC, or Sβ form of sickle cell disease and be aged between 16 and 17 years. The randomisation in a 1:1 ratio assigns to Arm A or B. The primary outcome is the number of hospital admissions and emergencies for complications in the index hospital, in the 2 years after the first consultation in the adult department of care. Secondary outcomes consider the quality of life, but also include coping skills such as sense of self-efficacy and disease knowledge. To provide patient and parent knowledge and coping skills, the transition programme is composed of three axes: educational, psychological, and social, conducted individually and in groups.
DISCUSSION
By providing self-care knowledge and coping skills related to SCD and therapeutics, helping empower patientsin relation to pain management and emotions, and facilitating the relationship to oneself, others, and care in Arm B of the DREPADO study, we believe that the morbidity and mortality of patients with SCD may be reduced after the proposed paediatric-adult transition programme.
TRIAL REGISTRATION
ClinicalTrials.gov, ID: NCT03786549; registered on 17 December 2018; https://clinicaltrials.gov/.
DOI: 10.1186/s13063-019-4009-9
PubMed: 32039737
PubMed Central: PMC7008523
Affiliations:
- France
- Auvergne-Rhône-Alpes, Rhône-Alpes, Île-de-France
- Lyon, Paris
- Université Claude Bernard Lyon 1
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of a paediatric-adult care transition programme on the health status of patients with sickle cell disease: study protocol for a randomised controlled trial (the DREPADO trial).</title><author><name sortKey="Hoegy, Delphine" sort="Hoegy, Delphine" uniqKey="Hoegy D" first="Delphine" last="Hoegy">Delphine Hoegy</name><affiliation wicri:level="3"><nlm:affiliation>EA 4129 P2S Parcours Santé Systémique-Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France. delphine.hoegy@chu-lyon.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EA 4129 P2S Parcours Santé Systémique-Université Claude Bernard Lyon 1, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Pharmacie Hôpital Edouard Herriot, Hospices Civils de Lyon, 5 place d'Arsonval, 69003, Lyon, France. delphine.hoegy@chu-lyon.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pharmacie Hôpital Edouard Herriot, Hospices Civils de Lyon, 5 place d'Arsonval, 69003, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Institut des Sciences Pharmaceutiques et Biologiques, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France. delphine.hoegy@chu-lyon.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut des Sciences Pharmaceutiques et Biologiques, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName><orgName type="university">Université Claude Bernard Lyon 1</orgName></affiliation><affiliation wicri:level="3"><nlm:affiliation>INSERM U1111-CNRS UMR 5308 ENS Lyon, Université Lyon 1, Lyon, France. delphine.hoegy@chu-lyon.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U1111-CNRS UMR 5308 ENS Lyon, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Bleyzac, Nathalie" sort="Bleyzac, Nathalie" uniqKey="Bleyzac N" first="Nathalie" last="Bleyzac">Nathalie Bleyzac</name><affiliation wicri:level="4"><nlm:affiliation>EMR 3738, PK/PD modeling in oncology, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EMR 3738, PK/PD modeling in oncology, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName><orgName type="university">Université Claude Bernard Lyon 1</orgName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Centre Antipoison, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre Antipoison, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Gauthier Vasserot, Alexandra" sort="Gauthier Vasserot, Alexandra" uniqKey="Gauthier Vasserot A" first="Alexandra" last="Gauthier-Vasserot">Alexandra Gauthier-Vasserot</name><affiliation wicri:level="3"><nlm:affiliation>INSERM U1111-CNRS UMR 5308 ENS Lyon, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U1111-CNRS UMR 5308 ENS Lyon, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Institut d'Hématologie et d'Oncologie Pédiatrique de Lyon, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut d'Hématologie et d'Oncologie Pédiatrique de Lyon, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName><orgName type="university">Université Claude Bernard Lyon 1</orgName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), PRES Sorbonne, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), PRES Sorbonne, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Cannas, Giovanna" sort="Cannas, Giovanna" uniqKey="Cannas G" first="Giovanna" last="Cannas">Giovanna Cannas</name><affiliation wicri:level="3"><nlm:affiliation>INSERM U1111-CNRS UMR 5308 ENS Lyon, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U1111-CNRS UMR 5308 ENS Lyon, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName><orgName type="university">Université Claude Bernard Lyon 1</orgName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), PRES Sorbonne, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), PRES Sorbonne, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Médecine Interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Médecine Interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Denis, Angelique" sort="Denis, Angelique" uniqKey="Denis A" first="Angélique" last="Denis">Angélique Denis</name><affiliation wicri:level="3"><nlm:affiliation>Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pôle Santé Publique, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Hot, Arnaud" sort="Hot, Arnaud" uniqKey="Hot A" first="Arnaud" last="Hot">Arnaud Hot</name><affiliation wicri:level="3"><nlm:affiliation>Médecine Interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Médecine Interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Centre de Référence Constitutif Syndromes Drépanocytaires Majeurs, Thalassémies et Autres Pathologies Rares du Globule Rouge et de l'Erythropoïèse, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre de Référence Constitutif Syndromes Drépanocytaires Majeurs, Thalassémies et Autres Pathologies Rares du Globule Rouge et de l'Erythropoïèse, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Bertrand, Yves" sort="Bertrand, Yves" uniqKey="Bertrand Y" first="Yves" last="Bertrand">Yves Bertrand</name><affiliation wicri:level="3"><nlm:affiliation>INSERM U1111-CNRS UMR 5308 ENS Lyon, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U1111-CNRS UMR 5308 ENS Lyon, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Institut d'Hématologie et d'Oncologie Pédiatrique de Lyon, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut d'Hématologie et d'Oncologie Pédiatrique de Lyon, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Centre de Référence Constitutif Syndromes Drépanocytaires Majeurs, Thalassémies et Autres Pathologies Rares du Globule Rouge et de l'Erythropoïèse, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre de Référence Constitutif Syndromes Drépanocytaires Majeurs, Thalassémies et Autres Pathologies Rares du Globule Rouge et de l'Erythropoïèse, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Occelli, Pauline" sort="Occelli, Pauline" uniqKey="Occelli P" first="Pauline" last="Occelli">Pauline Occelli</name><affiliation wicri:level="3"><nlm:affiliation>Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pôle Santé Publique, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>EA 7425 HESPER Health Services and Performance Research, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EA 7425 HESPER Health Services and Performance Research, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Touzet, Sandrine" sort="Touzet, Sandrine" uniqKey="Touzet S" first="Sandrine" last="Touzet">Sandrine Touzet</name><affiliation wicri:level="3"><nlm:affiliation>Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pôle Santé Publique, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>EA 7425 HESPER Health Services and Performance Research, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EA 7425 HESPER Health Services and Performance Research, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Dussart, Claude" sort="Dussart, Claude" uniqKey="Dussart C" first="Claude" last="Dussart">Claude Dussart</name><affiliation wicri:level="3"><nlm:affiliation>EA 4129 P2S Parcours Santé Systémique-Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EA 4129 P2S Parcours Santé Systémique-Université Claude Bernard Lyon 1, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Pharmacie Centrale, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pharmacie Centrale, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Janoly Dumenil, Audrey" sort="Janoly Dumenil, Audrey" uniqKey="Janoly Dumenil A" first="Audrey" last="Janoly-Dumenil">Audrey Janoly-Dumenil</name><affiliation wicri:level="3"><nlm:affiliation>EA 4129 P2S Parcours Santé Systémique-Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EA 4129 P2S Parcours Santé Systémique-Université Claude Bernard Lyon 1, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Pharmacie Hôpital Edouard Herriot, Hospices Civils de Lyon, 5 place d'Arsonval, 69003, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pharmacie Hôpital Edouard Herriot, Hospices Civils de Lyon, 5 place d'Arsonval, 69003, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Institut des Sciences Pharmaceutiques et Biologiques, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut des Sciences Pharmaceutiques et Biologiques, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName><orgName type="university">Université Claude Bernard Lyon 1</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32039737</idno><idno type="pmid">32039737</idno><idno type="doi">10.1186/s13063-019-4009-9</idno><idno type="pmc">PMC7008523</idno><idno type="wicri:Area/Main/Corpus">000236</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000236</idno><idno type="wicri:Area/Main/Curation">000236</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000236</idno><idno type="wicri:Area/Main/Exploration">000236</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of a paediatric-adult care transition programme on the health status of patients with sickle cell disease: study protocol for a randomised controlled trial (the DREPADO trial).</title><author><name sortKey="Hoegy, Delphine" sort="Hoegy, Delphine" uniqKey="Hoegy D" first="Delphine" last="Hoegy">Delphine Hoegy</name><affiliation wicri:level="3"><nlm:affiliation>EA 4129 P2S Parcours Santé Systémique-Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France. delphine.hoegy@chu-lyon.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EA 4129 P2S Parcours Santé Systémique-Université Claude Bernard Lyon 1, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Pharmacie Hôpital Edouard Herriot, Hospices Civils de Lyon, 5 place d'Arsonval, 69003, Lyon, France. delphine.hoegy@chu-lyon.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pharmacie Hôpital Edouard Herriot, Hospices Civils de Lyon, 5 place d'Arsonval, 69003, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Institut des Sciences Pharmaceutiques et Biologiques, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France. delphine.hoegy@chu-lyon.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut des Sciences Pharmaceutiques et Biologiques, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName><orgName type="university">Université Claude Bernard Lyon 1</orgName></affiliation><affiliation wicri:level="3"><nlm:affiliation>INSERM U1111-CNRS UMR 5308 ENS Lyon, Université Lyon 1, Lyon, France. delphine.hoegy@chu-lyon.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U1111-CNRS UMR 5308 ENS Lyon, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Bleyzac, Nathalie" sort="Bleyzac, Nathalie" uniqKey="Bleyzac N" first="Nathalie" last="Bleyzac">Nathalie Bleyzac</name><affiliation wicri:level="4"><nlm:affiliation>EMR 3738, PK/PD modeling in oncology, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EMR 3738, PK/PD modeling in oncology, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName><orgName type="university">Université Claude Bernard Lyon 1</orgName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Centre Antipoison, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre Antipoison, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Gauthier Vasserot, Alexandra" sort="Gauthier Vasserot, Alexandra" uniqKey="Gauthier Vasserot A" first="Alexandra" last="Gauthier-Vasserot">Alexandra Gauthier-Vasserot</name><affiliation wicri:level="3"><nlm:affiliation>INSERM U1111-CNRS UMR 5308 ENS Lyon, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U1111-CNRS UMR 5308 ENS Lyon, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Institut d'Hématologie et d'Oncologie Pédiatrique de Lyon, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut d'Hématologie et d'Oncologie Pédiatrique de Lyon, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName><orgName type="university">Université Claude Bernard Lyon 1</orgName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), PRES Sorbonne, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), PRES Sorbonne, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Cannas, Giovanna" sort="Cannas, Giovanna" uniqKey="Cannas G" first="Giovanna" last="Cannas">Giovanna Cannas</name><affiliation wicri:level="3"><nlm:affiliation>INSERM U1111-CNRS UMR 5308 ENS Lyon, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U1111-CNRS UMR 5308 ENS Lyon, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName><orgName type="university">Université Claude Bernard Lyon 1</orgName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), PRES Sorbonne, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), PRES Sorbonne, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Médecine Interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Médecine Interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Denis, Angelique" sort="Denis, Angelique" uniqKey="Denis A" first="Angélique" last="Denis">Angélique Denis</name><affiliation wicri:level="3"><nlm:affiliation>Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pôle Santé Publique, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Hot, Arnaud" sort="Hot, Arnaud" uniqKey="Hot A" first="Arnaud" last="Hot">Arnaud Hot</name><affiliation wicri:level="3"><nlm:affiliation>Médecine Interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Médecine Interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Centre de Référence Constitutif Syndromes Drépanocytaires Majeurs, Thalassémies et Autres Pathologies Rares du Globule Rouge et de l'Erythropoïèse, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre de Référence Constitutif Syndromes Drépanocytaires Majeurs, Thalassémies et Autres Pathologies Rares du Globule Rouge et de l'Erythropoïèse, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Bertrand, Yves" sort="Bertrand, Yves" uniqKey="Bertrand Y" first="Yves" last="Bertrand">Yves Bertrand</name><affiliation wicri:level="3"><nlm:affiliation>INSERM U1111-CNRS UMR 5308 ENS Lyon, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U1111-CNRS UMR 5308 ENS Lyon, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Institut d'Hématologie et d'Oncologie Pédiatrique de Lyon, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut d'Hématologie et d'Oncologie Pédiatrique de Lyon, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Centre de Référence Constitutif Syndromes Drépanocytaires Majeurs, Thalassémies et Autres Pathologies Rares du Globule Rouge et de l'Erythropoïèse, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre de Référence Constitutif Syndromes Drépanocytaires Majeurs, Thalassémies et Autres Pathologies Rares du Globule Rouge et de l'Erythropoïèse, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Occelli, Pauline" sort="Occelli, Pauline" uniqKey="Occelli P" first="Pauline" last="Occelli">Pauline Occelli</name><affiliation wicri:level="3"><nlm:affiliation>Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pôle Santé Publique, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>EA 7425 HESPER Health Services and Performance Research, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EA 7425 HESPER Health Services and Performance Research, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Touzet, Sandrine" sort="Touzet, Sandrine" uniqKey="Touzet S" first="Sandrine" last="Touzet">Sandrine Touzet</name><affiliation wicri:level="3"><nlm:affiliation>Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pôle Santé Publique, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>EA 7425 HESPER Health Services and Performance Research, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EA 7425 HESPER Health Services and Performance Research, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Dussart, Claude" sort="Dussart, Claude" uniqKey="Dussart C" first="Claude" last="Dussart">Claude Dussart</name><affiliation wicri:level="3"><nlm:affiliation>EA 4129 P2S Parcours Santé Systémique-Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EA 4129 P2S Parcours Santé Systémique-Université Claude Bernard Lyon 1, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Pharmacie Centrale, Hospices Civils de Lyon, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pharmacie Centrale, Hospices Civils de Lyon, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Janoly Dumenil, Audrey" sort="Janoly Dumenil, Audrey" uniqKey="Janoly Dumenil A" first="Audrey" last="Janoly-Dumenil">Audrey Janoly-Dumenil</name><affiliation wicri:level="3"><nlm:affiliation>EA 4129 P2S Parcours Santé Systémique-Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>EA 4129 P2S Parcours Santé Systémique-Université Claude Bernard Lyon 1, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Pharmacie Hôpital Edouard Herriot, Hospices Civils de Lyon, 5 place d'Arsonval, 69003, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pharmacie Hôpital Edouard Herriot, Hospices Civils de Lyon, 5 place d'Arsonval, 69003, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Institut des Sciences Pharmaceutiques et Biologiques, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut des Sciences Pharmaceutiques et Biologiques, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName><orgName type="university">Université Claude Bernard Lyon 1</orgName></affiliation></author></analytic><series><title level="j">Trials</title><idno type="eISSN">1745-6215</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptation, Psychological (MeSH)</term><term>Adolescent (MeSH)</term><term>Awareness (MeSH)</term><term>Emotions (MeSH)</term><term>Female (MeSH)</term><term>Health Status (MeSH)</term><term>Hemoglobin SC Disease (blood)</term><term>Hemoglobin SC Disease (physiopathology)</term><term>Hemoglobin SC Disease (psychology)</term><term>Hemoglobin, Sickle (MeSH)</term><term>Humans (MeSH)</term><term>Male (MeSH)</term><term>Multicenter Studies as Topic (MeSH)</term><term>Pain Management (MeSH)</term><term>Patient Readmission (MeSH)</term><term>Quality of Life (MeSH)</term><term>Randomized Controlled Trials as Topic (MeSH)</term><term>Self Care (MeSH)</term><term>Self Efficacy (MeSH)</term><term>Transition to Adult Care (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adaptation psychologique (MeSH)</term><term>Adolescent (MeSH)</term><term>Auto-efficacité (MeSH)</term><term>Autosoins (MeSH)</term><term>Conscience immédiate (MeSH)</term><term>Drépanocytose SC (physiopathologie)</term><term>Drépanocytose SC (psychologie)</term><term>Drépanocytose SC (sang)</term><term>Essais contrôlés randomisés comme sujet (MeSH)</term><term>Femelle (MeSH)</term><term>Gestion de la douleur (MeSH)</term><term>Humains (MeSH)</term><term>Hémoglobine S (MeSH)</term><term>Mâle (MeSH)</term><term>Qualité de vie (MeSH)</term><term>Réadmission du patient (MeSH)</term><term>Transition aux soins pour adultes (MeSH)</term><term>Émotions (MeSH)</term><term>État de santé (MeSH)</term><term>Études multicentriques comme sujet (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Hemoglobin, Sickle</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Hemoglobin SC Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Drépanocytose SC</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Hemoglobin SC Disease</term></keywords><keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Drépanocytose SC</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Hemoglobin SC Disease</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Drépanocytose SC</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adaptation, Psychological</term><term>Adolescent</term><term>Awareness</term><term>Emotions</term><term>Female</term><term>Health Status</term><term>Humans</term><term>Male</term><term>Multicenter Studies as Topic</term><term>Pain Management</term><term>Patient Readmission</term><term>Quality of Life</term><term>Randomized Controlled Trials as Topic</term><term>Self Care</term><term>Self Efficacy</term><term>Transition to Adult Care</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adaptation psychologique</term><term>Adolescent</term><term>Auto-efficacité</term><term>Autosoins</term><term>Conscience immédiate</term><term>Essais contrôlés randomisés comme sujet</term><term>Femelle</term><term>Gestion de la douleur</term><term>Humains</term><term>Hémoglobine S</term><term>Mâle</term><term>Qualité de vie</term><term>Réadmission du patient</term><term>Transition aux soins pour adultes</term><term>Émotions</term><term>État de santé</term><term>Études multicentriques comme sujet</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Thanks to advancements in medical care, a majority of patients with sickle cell disease (SCD) worldwide live beyond 18 years of age, and therefore, patients initially followed in paediatric departments are then transferred to adult departments. This paediatric-adult care transition is a period with an increased risk of discontinuity of care and subsequent morbidity and mortality. During this period, the patient will have to manage new interlocutors and places of care, and personal issues related to the period of adolescence. To take into consideration all these aspects, an interesting approach is to use the whole system approach to the patient, as presented in the biopsychosocial approach. The aim of this trial is to evaluate the impact of the proposed biopsychosocial paediatric-adult transition programme.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>The DREPADO study is a multicentre randomised control trial comparing a control group (Arm A) to an interventional group with a paediatric-adult transition programme based on a biopsychosocial approach (Arm B). To be included, patients should have the SS, SC, or Sβ form of sickle cell disease and be aged between 16 and 17 years. The randomisation in a 1:1 ratio assigns to Arm A or B. The primary outcome is the number of hospital admissions and emergencies for complications in the index hospital, in the 2 years after the first consultation in the adult department of care. Secondary outcomes consider the quality of life, but also include coping skills such as sense of self-efficacy and disease knowledge. To provide patient and parent knowledge and coping skills, the transition programme is composed of three axes: educational, psychological, and social, conducted individually and in groups.</p></div><div type="abstract" xml:lang="en"><p><b>DISCUSSION</b></p><p>By providing self-care knowledge and coping skills related to SCD and therapeutics, helping empower patientsin relation to pain management and emotions, and facilitating the relationship to oneself, others, and care in Arm B of the DREPADO study, we believe that the morbidity and mortality of patients with SCD may be reduced after the proposed paediatric-adult transition programme.</p></div><div type="abstract" xml:lang="en"><p><b>TRIAL REGISTRATION</b></p><p>ClinicalTrials.gov, ID: NCT03786549; registered on 17 December 2018; https://clinicaltrials.gov/.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32039737</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>10</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>Impact of a paediatric-adult care transition programme on the health status of patients with sickle cell disease: study protocol for a randomised controlled trial (the DREPADO trial).</ArticleTitle><Pagination><MedlinePgn>152</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-019-4009-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Thanks to advancements in medical care, a majority of patients with sickle cell disease (SCD) worldwide live beyond 18 years of age, and therefore, patients initially followed in paediatric departments are then transferred to adult departments. This paediatric-adult care transition is a period with an increased risk of discontinuity of care and subsequent morbidity and mortality. During this period, the patient will have to manage new interlocutors and places of care, and personal issues related to the period of adolescence. To take into consideration all these aspects, an interesting approach is to use the whole system approach to the patient, as presented in the biopsychosocial approach. The aim of this trial is to evaluate the impact of the proposed biopsychosocial paediatric-adult transition programme.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The DREPADO study is a multicentre randomised control trial comparing a control group (Arm A) to an interventional group with a paediatric-adult transition programme based on a biopsychosocial approach (Arm B). To be included, patients should have the SS, SC, or Sβ form of sickle cell disease and be aged between 16 and 17 years. The randomisation in a 1:1 ratio assigns to Arm A or B. The primary outcome is the number of hospital admissions and emergencies for complications in the index hospital, in the 2 years after the first consultation in the adult department of care. Secondary outcomes consider the quality of life, but also include coping skills such as sense of self-efficacy and disease knowledge. To provide patient and parent knowledge and coping skills, the transition programme is composed of three axes: educational, psychological, and social, conducted individually and in groups.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">By providing self-care knowledge and coping skills related to SCD and therapeutics, helping empower patientsin relation to pain management and emotions, and facilitating the relationship to oneself, others, and care in Arm B of the DREPADO study, we believe that the morbidity and mortality of patients with SCD may be reduced after the proposed paediatric-adult transition programme.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov, ID: NCT03786549; registered on 17 December 2018; https://clinicaltrials.gov/.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hoegy</LastName><ForeName>Delphine</ForeName><Initials>D</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-8659-6073</Identifier><AffiliationInfo><Affiliation>EA 4129 P2S Parcours Santé Systémique-Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France. delphine.hoegy@chu-lyon.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacie Hôpital Edouard Herriot, Hospices Civils de Lyon, 5 place d'Arsonval, 69003, Lyon, France. delphine.hoegy@chu-lyon.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut des Sciences Pharmaceutiques et Biologiques, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France. delphine.hoegy@chu-lyon.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U1111-CNRS UMR 5308 ENS Lyon, Université Lyon 1, Lyon, France. delphine.hoegy@chu-lyon.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bleyzac</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>EMR 3738, PK/PD modeling in oncology, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre Antipoison, Hospices Civils de Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gauthier-Vasserot</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>INSERM U1111-CNRS UMR 5308 ENS Lyon, Université Lyon 1, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut d'Hématologie et d'Oncologie Pédiatrique de Lyon, Hospices Civils de Lyon, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), PRES Sorbonne, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cannas</LastName><ForeName>Giovanna</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>INSERM U1111-CNRS UMR 5308 ENS Lyon, Université Lyon 1, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire Interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire d'Excellence du Globule Rouge (Labex GR-Ex), PRES Sorbonne, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Médecine Interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denis</LastName><ForeName>Angélique</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hot</LastName><ForeName>Arnaud</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Médecine Interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de Référence Constitutif Syndromes Drépanocytaires Majeurs, Thalassémies et Autres Pathologies Rares du Globule Rouge et de l'Erythropoïèse, Hospices Civils de Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertrand</LastName><ForeName>Yves</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>INSERM U1111-CNRS UMR 5308 ENS Lyon, Université Lyon 1, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut d'Hématologie et d'Oncologie Pédiatrique de Lyon, Hospices Civils de Lyon, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre de Référence Constitutif Syndromes Drépanocytaires Majeurs, Thalassémies et Autres Pathologies Rares du Globule Rouge et de l'Erythropoïèse, Hospices Civils de Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Occelli</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>EA 7425 HESPER Health Services and Performance Research, Université Lyon 1, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Touzet</LastName><ForeName>Sandrine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>EA 7425 HESPER Health Services and Performance Research, Université Lyon 1, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dussart</LastName><ForeName>Claude</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>EA 4129 P2S Parcours Santé Systémique-Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacie Centrale, Hospices Civils de Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janoly-Dumenil</LastName><ForeName>Audrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>EA 4129 P2S Parcours Santé Systémique-Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacie Hôpital Edouard Herriot, Hospices Civils de Lyon, 5 place d'Arsonval, 69003, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut des Sciences Pharmaceutiques et Biologiques, Université Claude Bernard Lyon 1, Université Lyon 1, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>DREPADO study group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03786549</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006451">Hemoglobin, Sickle</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="N">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001364" MajorTopicYN="N">Awareness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="Y">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006450" MajorTopicYN="N">Hemoglobin SC Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006451" MajorTopicYN="N">Hemoglobin, Sickle</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059408" MajorTopicYN="N">Pain Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010359" MajorTopicYN="N">Patient Readmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012648" MajorTopicYN="N">Self Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020377" MajorTopicYN="N">Self Efficacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060305" MajorTopicYN="Y">Transition to Adult Care</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Paediatric-adult care transition</Keyword><Keyword MajorTopicYN="N">Sickle cell disease</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Pivot</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pondarre</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galactéros</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fois</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Montalembert</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arlet</LastName><ForeName>J B</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elana</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michaux</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guitton</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chantalat</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eyssette-Guerreau</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blum</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32039737</ArticleId><ArticleId IdType="doi">10.1186/s13063-019-4009-9</ArticleId><ArticleId IdType="pii">10.1186/s13063-019-4009-9</ArticleId><ArticleId IdType="pmc">PMC7008523</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pediatrics. 2017 May;139(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">28557765</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr Psychol. 2016 Jun;41(5):543-54</Citation><ArticleIdList><ArticleId IdType="pubmed">26717957</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Haematol. 2014 Mar;164(5):630-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24345037</ArticleId></ArticleIdList></Reference><Reference><Citation>J Adolesc Health. 2017 Jan;60(1):120-123</Citation><ArticleIdList><ArticleId IdType="pubmed">27793727</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr Hematol Oncol. 2009 Aug;31(8):571-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19636266</ArticleId></ArticleIdList></Reference><Reference><Citation>Patient Prefer Adherence. 2018 Dec 12;12:2649-2660</Citation><ArticleIdList><ArticleId IdType="pubmed">30587937</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2010 Apr 29;115(17):3447-52</Citation><ArticleIdList><ArticleId IdType="pubmed">20194891</ArticleId></ArticleIdList></Reference><Reference><Citation>Encephale. 2004 Jul-Aug;30(4):409-10</Citation><ArticleIdList><ArticleId IdType="pubmed">15597462</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2010 Apr 7;303(13):1288-94</Citation><ArticleIdList><ArticleId IdType="pubmed">20371788</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2016 Apr 29;4:CD009794</Citation><ArticleIdList><ArticleId IdType="pubmed">27128768</ArticleId></ArticleIdList></Reference><Reference><Citation>Hematol Oncol Clin North Am. 1996 Dec;10(6):1255-64</Citation><ArticleIdList><ArticleId IdType="pubmed">8956014</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Health. 2017 Oct;32(10):1288-1307</Citation><ArticleIdList><ArticleId IdType="pubmed">28276742</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Pediatr. 2018 Jul 19;18(1):237</Citation><ArticleIdList><ArticleId IdType="pubmed">30025530</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Res Ther. 2000 Sep;38(9):951-63</Citation><ArticleIdList><ArticleId IdType="pubmed">10957829</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2018 Dec 6;13(12):e0208091</Citation><ArticleIdList><ArticleId IdType="pubmed">30521552</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Ther. 2015 Apr;32(4):293-305</Citation><ArticleIdList><ArticleId IdType="pubmed">25832469</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr Hematol Oncol. 2011 Jul;33(5):379-82</Citation><ArticleIdList><ArticleId IdType="pubmed">21602723</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hematol. 2011 Jan;86(1):116-20</Citation><ArticleIdList><ArticleId IdType="pubmed">21061308</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Rhône-Alpes</li><li>Île-de-France</li></region><settlement><li>Lyon</li><li>Paris</li></settlement><orgName><li>Université Claude Bernard Lyon 1</li></orgName></list><tree><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Hoegy, Delphine" sort="Hoegy, Delphine" uniqKey="Hoegy D" first="Delphine" last="Hoegy">Delphine Hoegy</name></region><name sortKey="Bertrand, Yves" sort="Bertrand, Yves" uniqKey="Bertrand Y" first="Yves" last="Bertrand">Yves Bertrand</name><name sortKey="Bertrand, Yves" sort="Bertrand, Yves" uniqKey="Bertrand Y" first="Yves" last="Bertrand">Yves Bertrand</name><name sortKey="Bertrand, Yves" sort="Bertrand, Yves" uniqKey="Bertrand Y" first="Yves" last="Bertrand">Yves Bertrand</name><name sortKey="Bleyzac, Nathalie" sort="Bleyzac, Nathalie" uniqKey="Bleyzac N" first="Nathalie" last="Bleyzac">Nathalie Bleyzac</name><name sortKey="Bleyzac, Nathalie" sort="Bleyzac, Nathalie" uniqKey="Bleyzac N" first="Nathalie" last="Bleyzac">Nathalie Bleyzac</name><name sortKey="Cannas, Giovanna" sort="Cannas, Giovanna" uniqKey="Cannas G" first="Giovanna" last="Cannas">Giovanna Cannas</name><name sortKey="Cannas, Giovanna" sort="Cannas, Giovanna" uniqKey="Cannas G" first="Giovanna" last="Cannas">Giovanna Cannas</name><name sortKey="Cannas, Giovanna" sort="Cannas, Giovanna" uniqKey="Cannas G" first="Giovanna" last="Cannas">Giovanna Cannas</name><name sortKey="Cannas, Giovanna" sort="Cannas, Giovanna" uniqKey="Cannas G" first="Giovanna" last="Cannas">Giovanna Cannas</name><name sortKey="Denis, Angelique" sort="Denis, Angelique" uniqKey="Denis A" first="Angélique" last="Denis">Angélique Denis</name><name sortKey="Dussart, Claude" sort="Dussart, Claude" uniqKey="Dussart C" first="Claude" last="Dussart">Claude Dussart</name><name sortKey="Dussart, Claude" sort="Dussart, Claude" uniqKey="Dussart C" first="Claude" last="Dussart">Claude Dussart</name><name sortKey="Gauthier Vasserot, Alexandra" sort="Gauthier Vasserot, Alexandra" uniqKey="Gauthier Vasserot A" first="Alexandra" last="Gauthier-Vasserot">Alexandra Gauthier-Vasserot</name><name sortKey="Gauthier Vasserot, Alexandra" sort="Gauthier Vasserot, Alexandra" uniqKey="Gauthier Vasserot A" first="Alexandra" last="Gauthier-Vasserot">Alexandra Gauthier-Vasserot</name><name sortKey="Gauthier Vasserot, Alexandra" sort="Gauthier Vasserot, Alexandra" uniqKey="Gauthier Vasserot A" first="Alexandra" last="Gauthier-Vasserot">Alexandra Gauthier-Vasserot</name><name sortKey="Gauthier Vasserot, Alexandra" sort="Gauthier Vasserot, Alexandra" uniqKey="Gauthier Vasserot A" first="Alexandra" last="Gauthier-Vasserot">Alexandra Gauthier-Vasserot</name><name sortKey="Hoegy, Delphine" sort="Hoegy, Delphine" uniqKey="Hoegy D" first="Delphine" last="Hoegy">Delphine Hoegy</name><name sortKey="Hoegy, Delphine" sort="Hoegy, Delphine" uniqKey="Hoegy D" first="Delphine" last="Hoegy">Delphine Hoegy</name><name sortKey="Hoegy, Delphine" sort="Hoegy, Delphine" uniqKey="Hoegy D" first="Delphine" last="Hoegy">Delphine Hoegy</name><name sortKey="Hot, Arnaud" sort="Hot, Arnaud" uniqKey="Hot A" first="Arnaud" last="Hot">Arnaud Hot</name><name sortKey="Hot, Arnaud" sort="Hot, Arnaud" uniqKey="Hot A" first="Arnaud" last="Hot">Arnaud Hot</name><name sortKey="Janoly Dumenil, Audrey" sort="Janoly Dumenil, Audrey" uniqKey="Janoly Dumenil A" first="Audrey" last="Janoly-Dumenil">Audrey Janoly-Dumenil</name><name sortKey="Janoly Dumenil, Audrey" sort="Janoly Dumenil, Audrey" uniqKey="Janoly Dumenil A" first="Audrey" last="Janoly-Dumenil">Audrey Janoly-Dumenil</name><name sortKey="Janoly Dumenil, Audrey" sort="Janoly Dumenil, Audrey" uniqKey="Janoly Dumenil A" first="Audrey" last="Janoly-Dumenil">Audrey Janoly-Dumenil</name><name sortKey="Occelli, Pauline" sort="Occelli, Pauline" uniqKey="Occelli P" first="Pauline" last="Occelli">Pauline Occelli</name><name sortKey="Occelli, Pauline" sort="Occelli, Pauline" uniqKey="Occelli P" first="Pauline" last="Occelli">Pauline Occelli</name><name sortKey="Touzet, Sandrine" sort="Touzet, Sandrine" uniqKey="Touzet S" first="Sandrine" last="Touzet">Sandrine Touzet</name><name sortKey="Touzet, Sandrine" sort="Touzet, Sandrine" uniqKey="Touzet S" first="Sandrine" last="Touzet">Sandrine Touzet</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/AutomedicationFrancoV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000182 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000182 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= AutomedicationFrancoV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32039737
|texte= Impact of a paediatric-adult care transition programme on the health status of patients with sickle cell disease: study protocol for a randomised controlled trial (the DREPADO trial).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32039737" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AutomedicationFrancoV1
| This area was generated with Dilib version V0.6.38. |  |